Jana L. Markley

Jana L. Markley

Auto-generated profile, based on publicly available information

Jana L. Markley

Department of Chemistry, University of Kansas , 1251 Wescoe Hall Drive, Lawrence, Kansas 66054-7582, United States

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2020 in Communications Biology
Verified
Journal Article
Open access
PDF file
AGAndrew J. Gasparrini
Andrew J. Gasparrini
JMJana L. Markley
Jana L. Markley
HKHirdesh Kumar
Hirdesh Kumar
BWBin Wang
Bin Wang
LFLuting Fang
Luting Fang
GDGautam Dantas
Gautam Dantas
Tetracycline resistance by antibiotic inactivation was first identified in commensal organisms but has since been reported in environmental and pathogenic microbes. Here, we identify and characterize an expanded pool of tet(X)-like genes in environmental and human commensal metagenomes via inactivation by antibiotic selection of metagenomic libraries. These genes formed two distinct clades according to habitat of origin, and resistance phenotypes were similarly correlated. Each gene isolated from the human gut encodes resistance to all tetracyclines tested, including eravacycline and omadacycline. We report a biochemical and structural characterization of one enzyme, Tet(X7). Further, we identify Tet(X7) in a clinical Pseudomonas aeruginosa isolate and demonstrate its contribution to tetracycline resistance. Lastly, we show anhydrotetracycline and semi-synthetic analogues inhibit Tet(X7) to prevent enzymatic tetracycline degradation and increase tetracycline efficacy against strains expressing tet(X7). This work improves our understanding of resistance by tetracycline-inactivation and provides the foundation for an inhibition-based strategy for countering resistance.

30 May 2018 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
JMJana L. Markley
Jana L. Markley
TWTimothy A. Wencewicz
Timothy A. Wencewicz
Tetracyclines have been foundational antibacterial agents for more than 70 years. Renewed interest in tetracycline antibiotics is being driven by advancements in tetracycline synthesis and strategic scaffold modifications designed to overcome established clinical resistance mechanisms including efflux and ribosome protection. Emerging new resistance mechanisms, including enzymatic antibiotic inactivation, threaten recent progress on bringing these next-generation tetracyclines to the clinic. Here we review the current state of knowledge on the structure, mechanism, and inhibition of tetracycline-inactivating enzymes.

6 March 2023 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JRJohn T. Randolph
John T. Randolph
MOMatthew J. O’connor
Matthew J. O’connor
FHFei Han
Fei Han
CHCharles W. Hutchins
Charles W. Hutchins
YSY. Amy Siu
Y. Amy Siu
MKMichael E. Kort
Michael E. Kort

5 March 2019 in ACS Infectious Diseases
Verified
Journal Article
Closed access
JMJana L. Markley
Jana L. Markley
LFLuting Fang
Luting Fang
AGAndrew J. Gasparrini
Andrew J. Gasparrini
CSChanez T. Symister
Chanez T. Symister
HKHirdesh Kumar
Hirdesh Kumar
TWTimothy A. Wencewicz
Timothy A. Wencewicz

24 May 2013 in Chemistry – A European Journal
Verified
Journal Article
Closed access
PDF file
RCRambabu Chegondi
Rambabu Chegondi
SMSoma Maitra
Soma Maitra
JMJana L. Markley
Jana L. Markley
PHPaul R. Hanson
Paul R. Hanson

1 May 2018 in Tetrahedron
Verified
Journal Article
Closed access
JMJana L. Markley
Jana L. Markley
TMTyler L. Morse
Tyler L. Morse
NRNigam P. Rath
Nigam P. Rath
TWTimothy A. Wencewicz
Timothy A. Wencewicz